Terms: = Leukemia AND TCL1A, P56279, 8115, ENSG00000100721, TCL1 AND Treatment
92 results:
1. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract] [Full Text] [Related]
2. Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic leukemia.
Merchand-Reyes G; Santhanam R; Valencia-Pena ML; Kumar K; Mo X; Belay T; Woyach JA; Mundy-Bosse B; Tridandapani S; Butchar JP
Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140397
[TBL] [Abstract] [Full Text] [Related]
3. Long-Smoldering T-prolymphocytic leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract] [Full Text] [Related]
4. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract] [Full Text] [Related]
5. T-Cell Prolymphocytic leukemia: Diagnosis, Pathogenesis, and treatment.
Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
[TBL] [Abstract] [Full Text] [Related]
6. Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia.
Pagano G; Botana IF; Wierz M; Roessner PM; Ioannou N; Zhou X; Al-Hity G; Borne C; Gargiulo E; Gonder S; Qu B; Stamatopoulos B; Ramsay AG; Seiffert M; Largeot A; Moussay E; Paggetti J
Haematologica; 2023 Nov; 108(11):3011-3024. PubMed ID: 37345470
[TBL] [Abstract] [Full Text] [Related]
7. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract] [Full Text] [Related]
8. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
[TBL] [Abstract] [Full Text] [Related]
9. From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature.
Nahmod KA; Thakral B; Aakash FNU; Iyer SP; Medeiros LJ; Quesada AE
Ann Diagn Pathol; 2023 Feb; 62():152077. PubMed ID: 36549077
[TBL] [Abstract] [Full Text] [Related]
10. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
[TBL] [Abstract] [Full Text] [Related]
11. Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
Martines C; Chakraborty S; Vujovikj M; Gobessi S; Vaisitti T; Deaglio S; Laurenti L; Dimovski AJ; Efremov DG
Blood; 2022 Dec; 140(22):2335-2347. PubMed ID: 36084319
[TBL] [Abstract] [Full Text] [Related]
12. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.
Severin F; Urbani A; Varanita T; Bachmann M; Azzolini M; Martini V; Pizzi M; Tos APD; Frezzato F; Mattarei A; Ghia P; Bertilaccio MTS; Gulbins E; Paradisi C; Zoratti M; Semenzato GC; Leanza L; Trentin L; Szabò I
J Exp Clin Cancer Res; 2022 Feb; 41(1):64. PubMed ID: 35172855
[TBL] [Abstract] [Full Text] [Related]
13. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC; Müller A; Dheenadayalan RP; Endres S; Roessner PM; Seyfried F; Walliser C; Wist M; Qi J; Tausch E; Mertens D; Fox JA; Debatin KM; Meyer LH; Taverna P; Seiffert M; Gierschik P; Stilgenbauer S
Blood; 2022 Feb; 139(6):859-875. PubMed ID: 34662393
[TBL] [Abstract] [Full Text] [Related]
15. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract] [Full Text] [Related]
16. Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kumar NAN; Dubashi B; Aibor Dkhar S; Adithan C
PLoS One; 2021; 16(3):e0247989. PubMed ID: 33760860
[TBL] [Abstract] [Full Text] [Related]
17. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract] [Full Text] [Related]
18. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Chen TL; Harrington B; Truxall J; Wasmuth R; Prouty A; Sloan S; Lehman AM; Sampath D; Orlemans E; Baiocchi RA; Alinari L; Byrd JC; Woyach JA; Hertlein E
J Hematol Oncol; 2021 Feb; 14(1):36. PubMed ID: 33627156
[TBL] [Abstract] [Full Text] [Related]
19. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
[TBL] [Abstract] [Full Text] [Related]
20. AKT: a key to RT?
Brown JR
Blood; 2021 Feb; 137(5):582-584. PubMed ID: 33538799
[TBL] [Abstract] [Full Text] [Related]
[Next]
